688639 Anhui Huaheng Biotechnology Co.,Ltd.
- 37.35
- -1.51-3.89%
Anhui Huaheng Biotechnology Co.,Ltd. News
Huaheng Biotech (688639): Reduced amino acid prices are dragging down performance, and new projects are expected to be put into operation
Huaheng Biotech (688639): Valine prices are expected to stabilize and pay attention to the release of new products
Huaheng Biotech (688639): 3Q24's profit needs to be improved, diversified product layout opens up room for growth
Huaheng Biotech (688639): Short-term performance is under pressure, focus on the pace of new product release
Huaheng Biotech (688639): Product price changes affect profit in a single quarter, focus on the pace of implementation of new products
Huaheng Biotech (688639): The amino acid economy is weak under pressure from Q3 profits
Huaheng Biology (688639): Implementation of fixed increases to help implement new projects
Huaheng Biology (688639): Q2 performance is under pressure, waiting for new products to be released
Huaheng Biology (688639): Short-term performance is under pressure, medium- to long-term growth is clear
Huaheng Biotech (688639): Short-term profit pressure in a single quarter, focus on the pace of new product implementation
Huaheng Biology (688639): Successful construction of bio-methionine is expected to become the company's next growth point
Huaheng Biotech (688639): Performance increased year-on-year, new products are being released soon
Huaheng Biotech (688639): Net profit to mother in '23 +40.32% YoY, 24Q1 net profit to mother +6.62% YoY
Huaheng Biology (688639): 23 years of high performance, new product layout, gradual improvement of synthetic biology platform
Huaheng Biotech (688639): Net profit to mother in '23 +40.32% YoY, 24Q1 net profit to mother +6.62% YoY
Huaheng Biotech (688639): Performance increased year-on-year, and new construction projects continued to be put into operation
Huaheng Biotech (688639) Annual Report and '24 Quarterly Report Review: Net profit increased 40% year-on-year in '23, and major new products are expected to launch in '24
Minsheng Securities released a research report on April 23 stating that Huaheng Biotech (688639.SH) was given a recommended rating. The main reasons for the rating include: 1) falling valine prices dragged down performance, and volume compensation continu
Huaheng Biotech (688639): Valine price reduction drags down Q1 performance, new product release opens up room for growth
Huaheng Biology (688639): Single products are becoming more prominent due to low economic risks and high growth attributes
Analysis
Price Target
No Data
No Data